Clinical Trials

We are committed to translating discoveries in the laboratory into innovative clinical trials for childhood cancer and other life-threatening diseases. 

Patient Referrals
 

St. Jude clinical trials emphasize the innovative and collaborative research between our doctors and scientists, who work together to find cures for children.

Children who are referred for a clinical trial at St. Jude will receive leading therapies, including standard and investigational treatments, in a compassionate, supportive setting that meets the highest standards of care. We provide phase 1, phase 2 and phase 3 clinical trials in childhood cancer, hematology, infectious diseases, supportive care and healthy volunteer studies.

For Physicians

We invite referring physicians and other health care providers to subscribe to our monthly Clinical Trials Alert email. This newsletter will notify you of important research protocols at St. Jude, as well as new initiatives, research news and information at the hospital.

Subscribe to Physician Email Newsletter

 

Referral contact information

Contact the Physician/Patient Referral Office to refer a child to St. Jude.

Call: 
1-888-226-4343 (toll-free)

Fax:
901-595-4011

Email: 
referralinfo@stjude.org

Online:
Referral Contact Form

24-hour pager: 
1-800-349-4334

 

For Families

Taking part in clinical research is a decision that should be discussed with family members and your child's doctor. We hope you will find the information in this section helpful in making the best choices for your child.

Browse Clinical Trials

  1. Featured Trial

     

    LVXSCID-ND: Gene Transfer for X-Linked Severe Combined Immunodeficiency (SCID) in Newly Diagnosed Infants

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency Disease, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial
     

    CPPGAL: Characterization of the Patient Population with Galactosialidosis

    Diseases Treated:

    Galactosialidosis

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    ED0157: Phase 1 Pediatric PK/PD Study

    A Phase I, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

    Diseases Treated:

    For patients at risk for blood clots

    Eligibility:

    • Participant has a diagnosis requiring anticoagulant therapy.
    • Participant has completed their standard anticoagulant therapy.
    • Participant is not receiving active therapy for a malignant condition.
    • Participant is less than 18 years of age at the time of consent.
    • Participant and legal guardian agree to food and drug restrictions during study.
    View Trial

    EDO312: Edoxaban, a new Oral Anticoagulant, for Blood Clots in Children

    Phase III Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban with Standard Anticoagulant Therapy in Children with Venous Thromboembolism (VTE)

    Diseases Treated:

    Blood clots (venous thromboembolism)

    Eligibility:

    This clinical trial is open only to St. Jude patients.

    • Newborn to 17 years old (must be younger than 18)
    • Diagnosis of blood clot in a vein (venous thromboembolism, also called VTE)
    • Requires anticoagulant therapy for at least 90 days
    • Received at least 5 days of heparin therapy prior to study
    View Trial

    INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

    Diseases Treated:

    Non-malignant blood diseases (non-therapeutic)

    Eligibility:

    • Receiving therapy or a consultation for a non-malignant blood disorder
    • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
    View Trial

    LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

    Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

    • Diagnosis of sickle cell disease (SCD)
    • 16 to 20 years old
    • English is primary language
    View Trial

    LVXSCID-ND: Gene Transfer for X-Linked Severe Combined Immunodeficiency (SCID) in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency Disease, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial

    PKiDS: Pyruvate Kinase Deficiency (PKD) Natural History Study

    Diseases Treated:

    Pyruvate kinase deficiency (PKD)

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participants of all ages with biochemically or genetically diagnosed PKD.
    • Participants with a hemolytic anemia and a family member with genetically diagnosed PKD.
    • The participant or the guardian of the participant is willing and able to give written informed consent and/or assent.
    View Trial

    REHASH: Barriers to Hydroxyurea Adherence for Sickle Cell Disease

    Re-Aiming at Hydroxyurea Adherence for Sickle Cell with MHealth

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This study is limited to patients living in the Memphis, Tennessee region.

    Phase I

    Phase II

    • Diagnosis of sickle cell disease
    • Between 15 and 44.9 years old
    • Receiving hydroxyurea treatment for sickle cell disease
    • Owns a smart phone
    • Not currently receiving text messages for improving hydroxyurea adherence
    • Not currently undergoing hydroxyurea dose escalation
    • Not on any investigational new drug intervention study for sickle cell disease
    View Trial
  2. 10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell transplant at St. Jude Children’s Research Hospital using an unlicensed cord blood unit (CBU).
    • The patient has a disorder affecting the hematopoietic system that is either inherited, acquired, or a result from myeloablative treatment.
    View Trial

    BMTFU: Protocol for Collecting Long-Term Follow-Up Data on Recipients of Hematopoietic Stem Cell Transplant

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
    View Trial

    NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

    Diseases Treated:

    Leukemia and other blood diseases

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
    • Participant may be of any age and either gender.
    • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
    • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
    View Trial

    NMDPD: Protocol for a Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

    National Marrow Donor Program: A research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    SCIDBMT: Bone Marrow Transplant for Infants with Severe Combined Immunodeficiency (SCID)

    Haplocompatible Transplant Using TCRa/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

    Diseases Treated:

    Severe combined immunodeficiency (SCID)

    Eligibility:

    • Infant at least 2 months old with severe combined immunodeficiency (SCID)
    • Has suitable matched sibling donor or matched unrelated donor or a single haplotype matched family member donor
    View Trial

    SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

    A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

     

     

    View Trial

    SJHOME: At-Home Care after Stem Cell Transplant

    Health and Outpatient Management Experiences

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial open only to St. Jude patients.

    • 12 years old or younger
    • Has had a hematopoietic stem cell transplant (HCST)
    • Recruitment occurs within two weeks before or after discharge from transplant admission
    • Prescribed oral medication at discharge
    • Speaks and reads English
    View Trial
  3. ADV1416: A Study of Ramucirumab in Children with Solid Tumors and Brain Tumors

    Diseases Treated:

    Brain Tumors

    Solid Tumors

    Eligibility:

    • 12 months old or older and younger than 21 years old
    • Diagnosis:
      • Part A - Non-central nervous system (CNS) tumor that returned after treatment or did not respond to treatment
      • Part B – CNS tumor that returned after treatment or did not respond to treatment
    • No other proven therapy options
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Diseases Treated:

    Solid tumors, giomas, hystiocytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    CCL0922: Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

    Diseases Treated:

    Brain Tumor : Previously treated brain tumors

    Eligibility:

    • Age is > 6 years and < 17 years & 10 months at the time of study entry.
    • Off treatment and progression–free for at least 12 months and less than and equal to 14 years.
    • Diagnosis of a primary brain tumor treated with at least one of the following :
      • Neurosurgical resection of the brain tumor;
      • Cranial irradiation;
      • Any chemotherapy to treat the brain tumor
    View Trial

    CNS831: Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

    Diseases Treated:

    Intracranial ependymoma

    Eligibility:

    • Patient must be greater than 12 months of age and less than 21 years of age at enrollment
    • Patients with newly diagnosed intracranial ependymoma without evidence of metastatic disease (confirmed by MRI brain and spine along with lumbar puncture to check CSF)
    • Patients with diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma are not eligible
    • No prior treatment other than surgical intervention and corticosteriods
    View Trial

    LOXO-TRK: Testing Larotrectinib (LOXO-101) in Children with Advanced Solid Tumors or Brain Tumors

    Diseases Treated:

    Solid Tumors, Central Nervous System Tumors

    Eligibility:

    Phase 1

    • Birth through 21 years of age with locally advanced or metastatic solid tumor or primary CNS tumor that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Infants from birth and older with diagnosis of malignancy and with documented NTRK fusion that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery or limb amputation to achieve complete surgical resection

    Phase 2

    • Infants from birth and older at C1D1 with locally advanced or metastatic infantile fibrosarcoma OR
    • Birth through 21 years old at C1D1 with locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was not responsive to therapy and for which no standard or available curative therapy with a NTRK gene funsion OR
    • More than 21 years old with tumor diagnosis typical of a pediatric patient and an NTRK fusion
    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    Diseases Treated:

    Relapsed or refractory solid tumor

    Eligibility:

    • Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    MEMCRT: Memantine to Prevent Thinking Problems in Children Receiving Radiation for Certain Brain Tumors

    Diseases Treated:

    Brain Tumors

    Eligibility:

    • Between 6 and 21 years old
    • Diagnosis of localized low-grade gliomacraniopharyngioma, ependymoma or germ cell tumor 
    • Initiating focal cranial radiation therapy (photon or proton)
    • Able to swallow pills
    • Participant and parent/legal guardian speak, read and understand English
    • Normal ECG and laboratory tests
    • Adequate vision and hearing
    View Trial

    PBTC29: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Diseases Treated:

    Gliomas

    Eligibility:

    • Participant is ≥ 3 but ≤ 21 years of age at registration.
    • Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
    • Participant received last fraction of local irradiation to the primary tumor ≥ 12 weeks prior to registration, or does not apply.
    View Trial

    PBTC42: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

    Diseases Treated:

    Retinoblastoma protein 1 (Rb1) positive recurrent, progressive, or refractory central nervous system tumors

    Eligibility:

    • Between 4 and 21 years old
    • Able to swallow capsules
    • Rb1-positive recurrent, progressive or refractory central nervous system (CNS) tumor or DIPG
    • Stable neurological deficit for at least 1 week prior to enrollment
    • Last dose of known myelosuppressive anticancer chemotherapy at least 3 weeks prior to enrollment
    • Last fraction of focal irradiation > 2 weeks prior to enrollment
    View Trial

    PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

    Diseases Treated:

    Recurrent, progressive, or refractory high-grade gliomas

    Eligibility:

    • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
    • Participant is 1 to 18 years of age
    • Participant has bi-measurable disease on MRI 
    • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

     

    View Trial

    PBTC47: A Clinical Trial of the Drug, Panobinostat, in Children with Brain Tumors

    Diseases Treated:

    Diffuse Intrinsic Pontine Glioma (DIPG)

    Eligibility:

    • Diagnosis of progressive diffuse intrinsic pontine glioma (DIPG) or an increase in the bi-dimensional measurement or the appearance of a new tumor lesion since diagnosis
    • At least 2 but not more than 22 years old
    • Able to swallow capsules whole
    View Trial

    PBTC48: Study of the Optune Device in Children with Certain High-Grade Glioma and Ependymoma Brain Tumors

    Diseases Treated:

    High-grade glioma (HGG), ependymoma

    Eligibility:

    • Between 5 and 21 years old
    • Diagnosis of supratentorial high-grade glioma (HGG) or supratentorial ependymoma that is recurrent, progressive or refractory
    • Head circumference of at least 44 cm
    • Failed standard therapy with no other available treatment options
    • Recovered from prior chemotherapy, immunotherapy or radiotherapy
    • Willing and able to use the device at least 18 hours a day for at least 23 days and keep head shaved throughout treatment
    View Trial

    PNOC001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC #120817)

    Diseases Treated:

    Recurrent or progressive low grade gliomas (brain tumors)

    Eligibility:

    • Participant is three (3) to twenty-one (21) years of age.
    • Patient has refractory, progressive or recurrent confirmed low-grade glioma (WHO grade I or II) that was confirmed histologically at initial diagnosis.
    • Participant received his or her last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration, or at least six (6) weeks if nitrosourea.
    • Participant received his or her last dose of other investigational or biological agent more than seven (7) days prior to study entry.
    View Trial

    PNOC002: A Safety Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E in Children with Recurrent/Refractory BRAFV600E-Mutant Brain Tumors [PNOC-002, CC #120819, IND#116870 (exempt)]

    Diseases Treated:

    Brain tumors (recurrent and refractory)

    Eligibility:

    • 25 years or younger at time of registration
    • Histologically confirmed diagnosis of a primary central nervous system tumor
    • Positive test for the BRAFV600E or the BRAF Ins T mutation at a CLIA-approved laboratory
    View Trial

    PNOC007: H3.3K27M Peptide Vaccine for Children with Newly Diagnosed DIPG and Other Gliomas

    Diseases Treated:

    DIPG, glioma

    Eligibility:

    • Newly diagnosed diffuse intrinsic pontine glioma (DIPG) or other glioma
    • At least 3 years old and 21 or younger
    • Positive for HLA-A2
    • Has undergone tumor biopsy
    • Positive H3.3 K27M mutation in tumor
    • Has received standard radiation therapy
    • No prior chemotherapy, immunotherapy or bone marrow transplant
    View Trial

    RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

    Diseases Treated:

    Recurrent ependymoma

    Eligibility:

    • Progressive intracranial ependymoma after prior focal irradiation
    • At least 1 year old and younger than 21 years old
    • Adequate performance status (ECOG less than 3)
    • Does not require mechanical ventilation
    • Interval from start of initial radiation therapy to enrollment greater than 9 months
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJDAWN: Molecular-Based Therapy for Aggressive Brain and Spinal Cord Tumors in Children and Young Adults

    Diseases Treated:

    Brain tumor, medulloblastoma, ependymoma

    Eligibility:

    Ages for Study Enrollment

    • Stratum A (ribociclib and gemcitabine):  Between 1 and 24 years old with recurrent, progressive or refractory non-WNT,  non-sonic hedgehog (SHH) (NWNS) medulloblastoma or ependymoma
    • Stratum B (ribociclib and trametinib):  Between 1 and 24 years old with recurrent, progressive, or refractory central nervous system (CNS) tumors, including:
      • High-grade glioma
      • Atypical teratoid rhabdoid tumor (ATRT)
      • SHH and WNT medulloblastoma
      • CNS embryonal tumors [previously called PNET])
    • Stratum C (ribociclib and sonidegib):  Between 10 and 39 years old with recurrent, progressive, or refractory SHH medulloblastoma and copy number loss of 9q or PTCH1 mutation. (This stratum is only open to patients with SHH medulloblastoma who are fully grown.  Patients younger than 18 years old will have bone age to determine if fully grown)

    Screening Phase Eligibility

    Inclusion Criteria:

    • Participants with recurrent, progressive, or refractory brain tumors
    • At least 1 year old and younger than 25 years old at the time of screening. Exception: Participants with recurrent, progressive or refractory medulloblastoma who are at least 1 year old and younger than 40 years of age at the time of study screening are eligible for screening.
    • Participants and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.

    Exclusion Criteria:

    • Recurrent, progressive or refractory low grade glioma (LGG)
    • Prior exposure to a CDK4/6 inhibitor
    • History of clinically significant, uncontrolled heart disease and/or repolarization abnormalities
    • History of QTc prolongation
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • At least 3 years old and younger than 22 years old (Strata W, S or N) OR
    • At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SJPI3K: Phase I Study of GDC-0084 in Young Patients with Newly Diagnosed DIPG or other Gliomas after Radiation Therapy

    Diseases Treated:

    DIPG, diffuse midline glioma, H3 K27M-mutant glioma

    Eligibility:

    • Between 2 and 22 years old
    • Diagnosed with diffuse intrinsic pontine glioma (DIPG) or other midline glioma that has not spread
    • No prior therapy, other than surgery and/or steroids
    View Trial

    SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors

    Diseases Treated:

    Brain tumor

    Eligibility:

    This study is open only to patients at St. Jude Children’s Research Hospital.

    • Diagnosis of medulloblastoma or other brain tumor
    • Between 8 and 12 years old
    • At least 2 years after completion of therapy
    • Full-time student
    • Speaks English
    View Trial
  4. G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    LiSTENING: Learning in Story: Elicited Narrative Informs Navigating Genetics

    Eligibility:

    This is a non-therapeutic clinical trial open to St. Jude patients only.

    Participants have been pre-identified by the primary care team as an English-speaking, four-member family unit diagnosed with TP53 mutation.

    View Trial

    PG4KDS: Clinical Implementation of Pharmacogenetics

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients

    View Trial

    PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer

    Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection

    Diseases Treated:

    None

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to St. Jude patients.

    • Younger than 25 years
    • Undergoing cancer therapy at St. Jude Children’s Research Hospital
    • Considered to be at high risk of infection
    View Trial

    SJFAMILY: Study of Cancer in Families

    Familial Investigations of Childhood Cancer Predisposition

    Diseases Treated:

    Non-therapeutic clinical trial

    Eligibility:

    This is a non-therapeutic clinical trial that is open to children and adults with familial cancer and to their eligible family members.

    Note: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical genetic testing, please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for the SJFAMILY study, as outlined below, you may enroll regardless of the results of your clinical genetic testing.

    In this research study, the definition of “Familial Cancer” is met if any of the following is present:

    • An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
    • An individual who has been diagnosed  with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
    • An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome

    Eligible individuals include:

    • An individual who meets the definition of “Familial Cancer,” as above
    • Blood relatives of the above individual with familial cancer, who are affected or unaffected by cancer
    View Trial
  5. BUZZOFF: Antimalarial Drug Effectiveness in Healthy Adults

    First-in-Human, Dose-Escalation Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

    Diseases Treated:

    Malaria

    Eligibility:

    • Healthy male or female adults
    • Age 18 to 55 years old
    • Minimum weight of 50 kg with BMI between 18 and 34 kg/m^2
    • Females must be post-menopausal or have documented hysterectomy or bilateral oophorectomy
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial

    XPD12-077: Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    St. Jude patients:

    • Treated with an allogeneic bone marrow or stem cell transplant at St. Jude
    • 8 years of age or older
    • Younger than 21 at time of transplant
    • More than 5 years from date of transplant

    Healthy volunteers (comparison group):

    • 8 years of age or older
    • Primarily speaks English
    • No known history of serious illness
    View Trial
  6. HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    LCH-CLO: Clofarabine for Langerhans Cell Histiocytosis and LCH-related disorders

    Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-Related Disorders

    Diseases Treated:

    Langerhans cell histiocytosis and LCH-related disorders

    Eligibility:

    • Prior diagnosis of Langerhans cell histiocytosis or LCH-related disorder
    • Evidence of active disease
    • Performance Score > 70% (use Lansky score for age < 16 and Karnofsky score for age ≥16)
    • Any age
    • Adequate organ functions
    View Trial

    LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis

    International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

    Diseases Treated:

    Langerhans cell histiocytosis

    Eligibility:

    • Diagnosis of Langerhans cell histiocytosis
    • Younger than 18 years old
    • Meets inclusion criteria for the respective stratum

     

    View Trial
  7. GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
    View Trial

    HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    LVXSCID-ND: Gene Transfer for X-Linked Severe Combined Immunodeficiency (SCID) in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency Disease, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial

    SCIDBMT: Bone Marrow Transplant for Infants with Severe Combined Immunodeficiency (SCID)

    Haplocompatible Transplant Using TCRa/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

    Diseases Treated:

    Severe combined immunodeficiency (SCID)

    Eligibility:

    • Infant at least 2 months old with severe combined immunodeficiency (SCID)
    • Has suitable matched sibling donor or matched unrelated donor or a single haplotype matched family member donor
    View Trial
  8. AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

    Diseases Treated:

    HIV Infection

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • The subject has been enrolled on IMPAACT P1025.
    View Trial

    BUZZOFF: Antimalarial Drug Effectiveness in Healthy Adults

    First-in-Human, Dose-Escalation Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

    Diseases Treated:

    Malaria

    Eligibility:

    • Healthy male or female adults
    • Age 18 to 55 years old
    • Minimum weight of 50 kg with BMI between 18 and 34 kg/m^2
    • Females must be post-menopausal or have documented hysterectomy or bilateral oophorectomy
    View Trial

    CCL1034: Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

    Diseases Treated:

    Cancer or allogeneic hematopoietic cell transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant > 2 months of age and < 21 years of age at enrollment.
    • Participant has or is scheduled to have an external tunneled central venous catheter (CVC) (Broviacs, Hickmans, tunneled percutaneously inserted central PICCs), that is expected to remain in place for an additional > 3 months.
    • Participant with a current or previous line infection completed antibiotics > 14 days ago.
    View Trial

    CMX351: Experimental Drug Treatment for Adenovirus Infection

    Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

    Diseases Treated:

    Infectious Disease

    Eligibility:

    • 2 months old or older
    • Diagnosed with adenovirus (AdV) infection
    • Has symptoms related to AdV infection
    • Able to take and absorb oral medication
    • No previous treatment with brincidofovir (BCV)
    View Trial

    ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

    A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects

    Diseases Treated:

    HIV Infection

    Eligibility:

    • Participant does not have life expectancy of less than 1 year.
    • Participant does not have history of significant drug sensitivity or drug allergy.
    • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
    • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
    View Trial

    FLUTRAN: Flu Vaccine Dose Comparison in Children Who Have Had Stem Cell Transplants

    Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients

    Diseases Treated:

    Influenza

    Eligibility:

    • At least 3 years old and younger than 17
    • Allogeneic hematopoietic stem cell transplant recipient
    • At least 3 and not more than 35 months after transplant
    • Platelet count of at least 30,000
    View Trial

    GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

    A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014

    Diseases Treated:

    HIV/AIDS

    Eligibility:

    • Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
    • Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
    • Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
    View Trial

    IMPAACT2002: Behavioral Therapy and Medication for Depression among Youth with HIV

    Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the U.S.

    Diseases Treated:

    Depression

    Eligibility:

    • 12 to 24 years old
    • Receiving mental health or HIV-related care at participating IMPAACT site
    • HIV-positive
    • Diagnosis of nonpsychotic depression
    • Current depressive symptoms that warrant intervention
    • Reads and speaks English
    View Trial

    ORIOME: Mouth and Nose Microorganisms in Childhood Cancer Patients

    The Oronasal Microbiota in Pediatric Oncology Patients

    Diseases Treated:

    Non-Therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Between 4 and 21 years old
    • Newly confirmed diagnosis of acute myeloid leukemia (AML) or scheduled to receive conditioning for allogeneic hematopoietic stem cell transplantation within seven days
    • Receiving treatment at St. Jude Children’s Research Hospital
    View Trial

    P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

    Diseases Treated:

    Human Immunodeficiency Virus

    Eligibility:

    • At least 4 weeks old but younger than 18 years old
    • Confirmed HIV-1 infection
    • Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
    View Trial

    PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer

    Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection

    Diseases Treated:

    None

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to St. Jude patients.

    • Younger than 25 years
    • Undergoing cancer therapy at St. Jude Children’s Research Hospital
    • Considered to be at high risk of infection
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial
  9. Featured Trial

     

    TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

    Diseases Treated:

    Acute lymphoblastic leukemia (ALL)

    Eligibility:

    • Newly diagnosed ALL
    • 1 year of age or younger at the time of diagnosis
    • Has not had any — or has had limited — prior therapy
    • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
    View Trial
     

    ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

    Eligibility:

    • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
      • Come back after treatment the first time
      • Did not respond to treatment the first time
    • Less than 22 years of age
    • Does not have HIV or hepatitis B infection
    View Trial

    ALTE1631: Web-based Exercise Study for Children and Adolescents with Acute Lymphoblastic Leukemia

    Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    This is a non-therapeutic clinical trial open to patients receiving treatment at a Children’s Oncology Group (COG)-affiliated institution.

    • At least 8 years old and younger than 16 years old
    • Newly diagnosed acute lymphoblastic leukemia (ALL), in first remission
    • Completed chemotherapy within past 6 months
    • Performance status corresponding to ECOG scores of 0, 1, 2
    • Fewer than 420 minutes of moderate to vigorous physical activity (MVPA) over the last week
    • Access to smart phone (Android 4.3 or later, iOS 7.1 or later or computer with connection to the internet)
    • Able to write and read English (patient and at least one parent/guardian)
    • Not pregnant
    View Trial

    AML16: Epigenetic Priming in Patients with Acute Myeloid Leukemia

    Phase II Trial of Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    Diseases Treated:

    Acute myeloid leukemia (AML)

    Eligibility:

    • Diagnosis of one of the following:
      • Acute myeloid leukemia (AML)
      • 5% to 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality
      • Myeloid sarcoma
      • High grade myelodysplastic syndrome (MDS) with greater than 5% blasts
      • Treatment-related myeloid neoplasms, including AML and MDS
    • 28 days to 21 years old
    • No prior therapy, except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine
    • Not pregnant
    View Trial

    DSCOG: Learning, Behavior and Social Skills in Survivors of Childhood Leukemia with Down syndrome

    Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia with Down syndrome

    Diseases Treated:

    Leukemia

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients who were treated at St. Jude Children’s Research Hospital since 1980 and are currently followed at the hospital.

    • St. Jude Children’s Research Hospital patient with acute leukemia (i.e., ALL or AML)
    • Trisomy 21 Down syndrome diagnosis
    • Completed all cancer therapy at St. Jude since 1980 and at least six months prior to study visit
    • English as the primary language
    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

    Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years and younger
    • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
    • Has a suitable single haplotype-matched family member donor
    • High-risk hematologic malignancy, including certain diagnoses of:
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia (AML)
      • Chronic myelogenous leukemia (CML)
      • Myelodysplastic syndrome (MDS)
      • Hodgkin lymphoma
      • Non-Hodgkin lymphoma
    View Trial

    M16-106: Combination Chemotherapy for Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Phase I Study of Venetoclax with Navitoclax and Chemotherapy for Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Diseases Treated:

    Acute lymphoblastic leukemia, lymphoblastic lymphoma

    Eligibility:

    • Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) that has not responded to treatment or has come back after treatment
    • Between 4 and 45 years old
    • Weigh at least 20 kg (44 lbs)
    • Able to swallow pills

     

     

    View Trial

    NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

    Diseases Treated:

    Leukemia and other blood diseases

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
    • Participant may be of any age and either gender.
    • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
    • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    RELPALL: Phase I Study of Palbociclib with Chemotherapy in Children with Acute Lymphoblastic Leukemia

    Phase I Study of Palbociclib in Combination with Chemotherapy in Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    • Younger than 22 years old
    • Diagnosis of relapsed or refractory acute lymphoblastic leukemia (ALL)
    View Trial

    SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Diseases Treated:

    Relapsed or refractory leukemia or hematologic malignancies

    Eligibility:

    (Phase II)

    • 21 years of age or younger
    • Acute myeloid leukemia (AML)
    • No history of HIV infection
    View Trial

    SJBC3: Mature B-cell Lymphoma and Leukemia Study III

    Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
    • No previous treatment (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)
    View Trial

    SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

    A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

     

     

    View Trial

    TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

    Diseases Treated:

    Acute lymphoblastic leukemia (ALL)

    Eligibility:

    • Newly diagnosed ALL
    • 1 year of age or younger at the time of diagnosis
    • Has not had any — or has had limited — prior therapy
    • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
    View Trial

    TOT17: Total Therapy for Children with Acute Lymphoblastic Leukemia and Lymphoma

    Total Therapy Study 17 for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • Diagnosis of B-cell or T-cell acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy)
    • 1 to 18 years old
    • No prior therapy or limited prior therapy
    View Trial

    VENAML: Chemotherapy Combined with Venetoclax in Children with Refractory or Relapsed Acute Myeloid Leukemia

    A Phase I and Expansion Cohort Study of Venetoclax in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Diseases Treated:

    Acute myeloid leukemia (AML), acute undifferentiated leukemia, mixed phenotype acute leukemia

    Eligibility:

    • Diagnosis of relapsed or refractory acute myeloid leukemia (AML), acute undifferentiated leukemia or mixed phenotype acute leukemia 
    • At least 2 years old and younger than 22 years old
    • Recovered from acute effects of prior therapy and no evidence of graft-versus-host disease (GVHD)
    • Adequate liver, kidney and heart functions
    View Trial
  10. BMTFU: Protocol for Collecting Long-Term Follow-Up Data on Recipients of Hematopoietic Stem Cell Transplant

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    CCSS: Childhood Cancer Survivor Study

    Diseases Treated:

    Childhood cancer incidence and survival

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Newly diagnosed with cancer between January 1, 1970, and December 31, 1996
    • Survival five years from diagnosis
    • Age less than 21 years at the time of diagnosis of cancer
    • English or Spanish speaking and living in the United States or Canada at the time of diagnosis
    View Trial

    FRAILTY: A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer

    Diseases Treated:

    Long-term effects of childhood cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is enrolled on the SJLIFE protocol
    • Participant completed a baseline SJLIFE assessment between 4 and 6 years prior to FRAILTY enrollment.
    • Participant’s age was between the ages of 18-45 when baseline SJLIFE assessment was completed.
    • Participant is not currently receiving treatment for cancer.
    View Trial

    LACOUT: Lactation Outcomes among Survivors of Pediatric Cancer

    Eligibility:

    This is a non-therapeutic clinical trial open to St. Jude patients only.

    Participant is a St. Jude Life or ACT (After Completion of Therapy) patient.

    View Trial

    LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

    Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    For survivors of Hodgkin lymphoma

    Eligibility:

    • Females, 25 years of age or older.
    • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
    View Trial

    LTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2B Randomized Placebo-Controlled (Carvedilol) Trial

    Diseases Treated:

    Cancer

    Eligibility:

    • Younger than 21 years old at time of cancer diagnosis
    • Weigh ≥ 40 Kg
    • Lifetime cumulative anthracycline dose prior to age 22: total dose ≥ 250 mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy
    • Completed cancer treatment at least 2 years prior to study enrollment
    View Trial

    NEULS: Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant was enrolled on SJCRH TOTXV ALL protocol (or Best Clinical Management that followed the same treatment provided in the TOTXV protocol)
    • Minimum of five years post diagnosis of ALL
    • Minimum age of 8.0 years at time of follow-up evaluation
    View Trial

    ONFUNC: Functional Outcomes For Children, Adolescents, and Young Adults With Osteonecrosis Following Hip Core Decompression

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant has a diagnosis of osteonecrosis and a hematologic malignancy or sickle cell disease.
    • Participant is a candidate for hip core decompression surgery.
    • Participant is 8 to 29 years of age.
    View Trial

    PREVENT: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    Congestive heart failure

    Eligibility:

    • Participant is > 16 years of age.
    • Participant had cancer diagnosis < 21 years of age.
    • Participant has lifetime cumulative anthracycline dose > 300 mg/m2.
    • Participant is > 2 years since completion of treatment for cancer.
    View Trial

    PTSARC: Physical Therapy in Young Patients With Lower Extremity Malignancies Before Surgery

    Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed with a Lower Extremity Malignancy

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Please see clinical trial for full inclusion and exclusion eligibility criteria.
    View Trial

    REPS: Impact of Resistance Training–Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors

    Diseases Treated:

    Long-term effects of childhood cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Currently enrolled on the SJLIFE protocol
    • 18 to 49 years old
    • At least 10 years post first cancer diagnosis
    • Lives within a 45-minute drive of a Greater Memphis Area ATC Fitness Center
    • Speaks English
    • Low lean mass defined as either:
      • Body fat content of at least 25% in males or at least 35% in females OR
      • Age and sex-specific Relative Lean Muscle Mass Standard Deviation score <-1.0
    View Trial

    SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant was diagnosed with a childhood cancer which was treated or followed by St. Jude Children's Research Hospital
    • Participant completed treatment for disease at least ten years prior to entry in this study
    • Participant is willing to return to St. Jude for periodic evaluation
    View Trial

    SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • All patients being followed or treated at St. Jude Children’s Research Hospital for the diagnosis of childhood cancer
    • Patient has not been permanently discharged from care and follow-up
    View Trial
  11. Featured Trial

     
     

    ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

    Eligibility:

    • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
      • Come back after treatment the first time
      • Did not respond to treatment the first time
    • Less than 22 years of age
    • Does not have HIV or hepatitis B infection
    View Trial

    APNEA: Sleep Apnea in Hodgkin Lymphoma Survivors Treated with Radiation to the Chest

    Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated with Thoracic Radiation

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to former St. Jude patients, their family members and friends.

    Hodgkin lymphoma survivor

    • Current St. Jude LIFE participant, treated with thoracic radiation for Hodgkin lymphoma
    • At least 18 years old
    • At least 5 years from original diagnosis

    Comparison group

    • Sibling, parent, relative or friend of a current or former St. Jude patient
    • At least 18 years old
    View Trial

    EBV201: Immunotherapy for Epstein-Barr Virus-Associated Cancers

    Study of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) in EBV-Associated Viremia or Malignancies

    Diseases Treated:

    Lymphoma

    Eligibility:

    • Epstein-Barr Virus (EBV) lymphoma or EBV-associated lymphoproliferative disorder
    • Primary or acquired immunodeficiency
    • Appropriate HLA partially-matched and restricted EBV-Cytotoxic T Lymphocytes (EBV-CTLs)
    • No other satisfactory therapies available to treat EBV disease
    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

    Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years and younger
    • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
    • Has a suitable single haplotype-matched family member donor
    • High-risk hematologic malignancy, including certain diagnoses of:
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia (AML)
      • Chronic myelogenous leukemia (CML)
      • Myelodysplastic syndrome (MDS)
      • Hodgkin lymphoma
      • Non-Hodgkin lymphoma
    View Trial

    HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

    Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    • Diagnosis of early-stage Hodgkin lymphoma 
    • Hodgkin lymphoma that has not been previously treated
    • 21 years of age or younger
    View Trial

    LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

    Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    For survivors of Hodgkin lymphoma

    Eligibility:

    • Females, 25 years of age or older.
    • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    SJBC3: Mature B-cell Lymphoma and Leukemia Study III

    Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
    • No previous treatment (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)
    View Trial

    TOT17: Total Therapy for Children with Acute Lymphoblastic Leukemia and Lymphoma

    Total Therapy Study 17 for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • Diagnosis of B-cell or T-cell acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy)
    • 1 to 18 years old
    • No prior therapy or limited prior therapy
    View Trial
  12. CASELEARN: A Qualitative Case Study of the Experiences of Children with Cancer as they Learn about their Diagnosis and Treatment

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    Please see the eligibility section on the clinical trial for full inclusion and exclusion criteria.

    View Trial
  13. ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

    A Phase I/II Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan In Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant is >12 months and < 21 years of age at the time of study entry.
    • Participant has had histologic verification of malignancy at original diagnosis or relapse.
    • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
    • Participant has a relapsed or refractory solid tumor.
    View Trial

    ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

    A Phase I Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

    Diseases Treated:

    Solid Tumors

    Eligibility:

    • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
    • Fully recovered from the acute toxic effects of all prior anticancer therapy
    • At least 1 but not more than 21 years of age
    • Able to swallow tablets whole
    View Trial

    ADV1416: A Study of Ramucirumab in Children with Solid Tumors and Brain Tumors

    A Phase I Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

    Diseases Treated:

    Brain Tumors

    Solid Tumors

    Eligibility:

    • 12 months old or older and younger than 21 years old
    • Diagnosis:
      • Part A - Non-central nervous system (CNS) tumor that returned after treatment or did not respond to treatment
      • Part B – CNS tumor that returned after treatment or did not respond to treatment
    • No other proven therapy options
    View Trial

    ADVL1513: Entinostat for Children with Recurrent or Refractory Solid Tumors

    A Phase I Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

    Diseases Treated:

    Solid Tumor, CNS Tumor, Lymphoma

    Eligibility:

    • 12 months to 21 years old
    • Able to swallow whole tablets
    • Diagnosis of recurrent or refractory solid tumor, including CNS tumor and lymphoma
    View Trial

    ADVL1515: Prexasertib for Children with Recurrent or Refractory Solid Tumors

    A Phase I Study of LY2606368 (prexasertib mesylate monohydrate), A CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

    Diseases Treated:

    Solid Tumor, CNS Tumor

    Eligibility:

    • 12 months to 21 years old
    • Diagnosis of recurrent or refractory solid tumor, including CNS tumor
    View Trial

    ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

    Eligibility:

    • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
      • Come back after treatment the first time
      • Did not respond to treatment the first time
    • Less than 22 years of age
    • Does not have HIV or hepatitis B infection
    View Trial

    AOST1421: Combination Drug Therapy to Treat Patients with Recurrent Osteosarcoma

    A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma

    Diseases Treated:

    Osteosarcoma

    Eligibility:

    • Younger than 30 years old
    • Original diagnosis of osteosarcoma
    • Osteosarcoma has come back in the lungs after original treatment
    • Lung tumors have been removed surgically within the last 4 weeks before enrolling in the study
    View Trial

    BMNIRN: Talazoparib Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

    A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant has refractory or recurrent solid tumor for which there is no standard therapy.
    • Participant has had histologic verification of malignancy at original diagnosis or at the time of relapse.
    • Participant is twelve (12) months to twenty-five (25) years of age at the time of enrollment on study.
    • Participant life expectancy is at least eight (8) weeks. 
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advance BRAF V600-Mutation Positive Solid Tumors

    Diseases Treated:

    Solid tumors, giomas, hystiocytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    CCL0922: Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

    A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor (SCUSF 0901; ACCL0922)

    Diseases Treated:

    Brain Tumor : Previously treated brain tumors

    Eligibility:

    • Age is > 6 years and < 17 years & 10 months at the time of study entry.
    • Off treatment and progression–free for at least 12 months and less than and equal to 14 years.
    • Diagnosis of a primary brain tumor treated with at least one of the following :
      • Neurosurgical resection of the brain tumor;
      • Cranial irradiation;
      • Any chemotherapy to treat the brain tumor
    View Trial

    ED0157: Phase 1 Pediatric PK/PD Study

    A Phase I, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

    Diseases Treated:

    For patients at risk for blood clots

    Eligibility:

    • Participant has a diagnosis requiring anticoagulant therapy.
    • Participant has completed their standard anticoagulant therapy.
    • Participant is not receiving active therapy for a malignant condition.
    • Participant is less than 18 years of age at the time of consent.
    • Participant and legal guardian agree to food and drug restrictions during study.
    View Trial

    ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

    A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects

    Diseases Treated:

    HIV Infection

    Eligibility:

    • Participant does not have life expectancy of less than 1 year.
    • Participant does not have history of significant drug sensitivity or drug allergy.
    • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
    • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
    View Trial

    EWS1221: Phase III Study of Ganitumab with Chemotherapy for Patients with Metastatic Ewing Sarcoma

    Randomized Phase III Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

    Diseases Treated:

    Ewing sarcoma

    Eligibility:

    • Younger than or equal to 50 years old
    • Diagnosis of Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow or other metastatic site
    View Trial

    FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

    18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

    Diseases Treated:

    Neuroblastoma, pheochromocytoma

    Eligibility:

    This study is open to St. Jude patients only.

    • Known or suspected neuroblastoma or pheochromocytoma
    • At least 1 year old

     

    View Trial

    HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

    Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    • Diagnosis of early-stage Hodgkin lymphoma 
    • Hodgkin lymphoma that has not been previously treated
    • 21 years of age or younger
    View Trial

    HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

    Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

    Diseases Treated:

    Lymphocyte predominant Hodgkin lymphoma 

    Eligibility:

    • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
    • LPHL that has not been previously treated with chemotherapy or radiation therapy
    • 18 years of age or younger

     

    View Trial

    iRET: Intravitreal Chemotherapy for Children with Retinoblastoma

    Intravitreal Carboplatin for the Treatment of Participants with Recurrent or Refractory Intraocular Reintoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Age 17 or younger
    • Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
    View Trial

    LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

    Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    For survivors of Hodgkin lymphoma

    Eligibility:

    • Females, 25 years of age or older.
    • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
    View Trial

    LOXO-TRK: Testing Larotrectinib (LOXO-101) in Children with Advanced Solid Tumors or Brain Tumors

    A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors (LOXO-TRK-15003)

    Diseases Treated:

    Solid Tumors, Central Nervous System Tumors

    Eligibility:

    Phase 1

    • Birth through 21 years of age with locally advanced or metastatic solid tumor or primary CNS tumor that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Infants from birth and older with diagnosis of malignancy and with documented NTRK fusion that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery or limb amputation to achieve complete surgical resection

    Phase 2

    • Infants from birth and older at C1D1 with locally advanced or metastatic infantile fibrosarcoma OR
    • Birth through 21 years old at C1D1 with locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was not responsive to therapy and for which no standard or available curative therapy with a NTRK gene funsion OR
    • More than 21 years old with tumor diagnosis typical of a pediatric patient and an NTRK fusion
    View Trial

    LTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2B Randomized Placebo-Controlled (Carvedilol) Trial

    Diseases Treated:

    Cancer

    Eligibility:

    • Younger than 21 years old at time of cancer diagnosis
    • Weigh ≥ 40 Kg
    • Lifetime cumulative anthracycline dose prior to age 22: total dose ≥ 250 mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy
    • Completed cancer treatment at least 2 years prior to study enrollment
    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

    Diseases Treated:

    Relapsed or refractory solid tumor

    Eligibility:

    • Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma

    Eligibility:

    • Between 6 months and 18 years old with  diagnosis of advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma, or MSI-H solid tumor
      OR
    • Between 3 and 18 years of age with relapsed or refractory classical Hodgkin lymphoma
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    MEMCRT: Memantine to Prevent Thinking Problems in Children Receiving Radiation for Certain Brain Tumors

    Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study

    Diseases Treated:

    Brain Tumors

    Eligibility:

    • Between 6 and 21 years old
    • Diagnosis of localized low-grade gliomacraniopharyngioma, ependymoma or germ cell tumor 
    • Initiating focal cranial radiation therapy (photon or proton)
    • Able to swallow pills
    • Participant and parent/legal guardian speak, read and understand English
    • Normal ECG and laboratory tests
    • Adequate vision and hearing
    View Trial

    NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

    Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    • Younger than 19 years old
    • Newly diagnosed, advanced stage, high-risk neuroblastoma
    • Histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine
    • Adequate kidney and liver functions
    View Trial

    P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

    Diseases Treated:

    Human Immunodeficiency Virus

    Eligibility:

    • At least 4 weeks old but younger than 18 years old
    • Confirmed HIV-1 infection
    • Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
    View Trial

    PBTC29: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    A Phase I and Phase II and Re-treatment Study of AZD6244 for Recurrent or Refractory Low Grade Glioma (PBTC-029)

    Diseases Treated:

    Gliomas

    Eligibility:

    • Participant is ≥ 3 but ≤ 21 years of age at registration.
    • Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
    • Participant received last fraction of local irradiation to the primary tumor ≥ 12 weeks prior to registration, or does not apply.
    View Trial

    PBTC42: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

    Phase I Study of CDK 4-6 Inhibitor PD-0332991 (palbociclib; IBRANCE) in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors

    Diseases Treated:

    Retinoblastoma protein 1 (Rb1) positive recurrent, progressive, or refractory central nervous system tumors

    Eligibility:

    • Between 4 and 21 years old
    • Able to swallow capsules
    • Rb1-positive recurrent, progressive or refractory central nervous system (CNS) tumor or DIPG
    • Stable neurological deficit for at least 1 week prior to enrollment
    • Last dose of known myelosuppressive anticancer chemotherapy at least 3 weeks prior to enrollment
    • Last fraction of focal irradiation > 2 weeks prior to enrollment
    View Trial

    PBTC47: A Clinical Trial of the Drug, Panobinostat, in Children with Brain Tumors

    Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma (DIPG)

    Diseases Treated:

    Diffuse Intrinsic Pontine Glioma (DIPG)

    Eligibility:

    • Diagnosis of progressive diffuse intrinsic pontine glioma (DIPG) or an increase in the bi-dimensional measurement or the appearance of a new tumor lesion since diagnosis
    • At least 2 but not more than 22 years old
    • Able to swallow capsules whole
    View Trial

    PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease

    Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

    • Between 6 and 25 years old
    • Diagnosed with sickle cell disease
    • Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
    • Speaks English
    View Trial

    PNOC001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC #120817)

    Diseases Treated:

    Recurrent or progressive low grade gliomas (brain tumors)

    Eligibility:

    • Participant is three (3) to twenty-one (21) years of age.
    • Patient has refractory, progressive or recurrent confirmed low-grade glioma (WHO grade I or II) that was confirmed histologically at initial diagnosis.
    • Participant received his or her last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration, or at least six (6) weeks if nitrosourea.
    • Participant received his or her last dose of other investigational or biological agent more than seven (7) days prior to study entry.
    View Trial

    PNOC007: H3.3K27M Peptide Vaccine for Children with Newly Diagnosed DIPG and Other Gliomas

    H3.3K27M Specific Peptide Vaccine with Poly-ICLC for HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and Other Gliomas

    Diseases Treated:

    DIPG, glioma

    Eligibility:

    • Newly diagnosed diffuse intrinsic pontine glioma (DIPG) or other glioma
    • At least 3 years old and 21 or younger
    • Positive for HLA-A2
    • Has undergone tumor biopsy
    • Positive H3.3 K27M mutation in tumor
    • Has received standard radiation therapy
    • No prior chemotherapy, immunotherapy or bone marrow transplant
    View Trial

    PREVENT: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    Congestive heart failure

    Eligibility:

    • Participant is > 16 years of age.
    • Participant had cancer diagnosis < 21 years of age.
    • Participant has lifetime cumulative anthracycline dose > 300 mg/m2.
    • Participant is > 2 years since completion of treatment for cancer.
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

    A Phase II Trial of Surgery and Fractionated Re-irradiation for Recurrent Ependymoma

    Diseases Treated:

    Recurrent ependymoma

    Eligibility:

    • Progressive intracranial ependymoma after prior focal irradiation
    • At least 1 year old and younger than 21 years old
    • Adequate performance status (ECOG less than 3)
    • Does not require mechanical ventilation
    • Interval from start of initial radiation therapy to enrollment greater than 9 months
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial

    SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Diseases Treated:

    Relapsed or refractory leukemia or hematologic malignancies

    Eligibility:

    (Phase II)

    • 21 years of age or younger
    • Acute myeloid leukemia (AML)
    • No history of HIV infection
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial

    SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

    Phase II Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJDAWN: Molecular-Based Therapy for Aggressive Brain and Spinal Cord Tumors in Children and Young Adults

    Molecularly-Driven Doublet Therapy for All Children with Refractory or Recurrent CNS Malignant Neoplasms and Young Adults with Refractory or Recurrent SHH Medulloblastoma

    Diseases Treated:

    Brain tumor, medulloblastoma, ependymoma

    Eligibility:

    Ages for Study Enrollment

    • Stratum A (ribociclib and gemcitabine):  Between 1 and 24 years old with recurrent, progressive or refractory non-WNT,  non-sonic hedgehog (SHH) (NWNS) medulloblastoma or ependymoma
    • Stratum B (ribociclib and trametinib):  Between 1 and 24 years old with recurrent, progressive, or refractory central nervous system (CNS) tumors, including:
      • High-grade glioma
      • Atypical teratoid rhabdoid tumor (ATRT)
      • SHH and WNT medulloblastoma
      • CNS embryonal tumors [previously called PNET])
    • Stratum C (ribociclib and sonidegib):  Between 10 and 39 years old with recurrent, progressive, or refractory SHH medulloblastoma and copy number loss of 9q or PTCH1 mutation. (This stratum is only open to patients with SHH medulloblastoma who are fully grown.  Patients younger than 18 years old will have bone age to determine if fully grown)

    Screening Phase Eligibility

    Inclusion Criteria:

    • Participants with recurrent, progressive, or refractory brain tumors
    • At least 1 year old and younger than 25 years old at the time of screening. Exception: Participants with recurrent, progressive or refractory medulloblastoma who are at least 1 year old and younger than 40 years of age at the time of study screening are eligible for screening.
    • Participants and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.

    Exclusion Criteria:

    • Recurrent, progressive or refractory low grade glioma (LGG)
    • Prior exposure to a CDK4/6 inhibitor
    • History of clinically significant, uncontrolled heart disease and/or repolarization abnormalities
    • History of QTc prolongation
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • At least 3 years old and younger than 22 years old (Strata W, S or N) OR
    • At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SJPI3K: Phase I Study of GDC-0084 in Young Patients with Newly Diagnosed DIPG or other Gliomas after Radiation Therapy

    Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Other Diffuse Midline Gliomas after Radiation Therapy

    Diseases Treated:

    DIPG, diffuse midline glioma, H3 K27M-mutant glioma

    Eligibility:

    • Between 2 and 22 years old
    • Diagnosed with diffuse intrinsic pontine glioma (DIPG) or other midline glioma that has not spread
    • No prior therapy, other than surgery and/or steroids
    View Trial

    SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

    Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Newly diagnosed retinoblastoma that has not spread beyond the eye
    • Has not received previous treatment with chemotherapy or radiation therapy
    • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
    View Trial

    TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

    Diseases Treated:

    Acute lymphoblastic leukemia (ALL)

    Eligibility:

    • Newly diagnosed ALL
    • 1 year of age or younger at the time of diagnosis
    • Has not had any — or has had limited — prior therapy
    • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
    View Trial
  14. HAPDON1: How Donating Bone Marrow for Their Child’s Stem Cell Transplant Impacts Parents

    Impact of Donation on Parental Haplotype Donors (and Non-Donors) of Children Treated with Hematopoietic Cell Transplant

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial open only to parents of St. Jude patients.

    • Parent of a child who received a haploidentical or unrelated donor transplant at St. Jude Children’s Research Hospital between January 1, 2006 and December 31, 2015
    • Speaks and reads English
    View Trial

    IMPAACT2002: Behavioral Therapy and Medication for Depression among Youth with HIV

    Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the U.S.

    Diseases Treated:

    Depression

    Eligibility:

    • 12 to 24 years old
    • Receiving mental health or HIV-related care at participating IMPAACT site
    • HIV-positive
    • Diagnosis of nonpsychotic depression
    • Current depressive symptoms that warrant intervention
    • Reads and speaks English
    View Trial

    LITE: Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed with Solid Tumors: A Pilot Study

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • At least 12 years old 
    • Diagnosed with a solid tumor or lymphoma within the past 30 days 
    • Speaks, reads and writes in English or Spanish
    • No blindness or history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems 
    • Not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months
    • No laser corrective eye surgery in the past 30 days
    View Trial

    MEMCRT: Memantine to Prevent Thinking Problems in Children Receiving Radiation for Certain Brain Tumors

    Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study

    Diseases Treated:

    Brain Tumors

    Eligibility:

    • Between 6 and 21 years old
    • Diagnosis of localized low-grade gliomacraniopharyngioma, ependymoma or germ cell tumor 
    • Initiating focal cranial radiation therapy (photon or proton)
    • Able to swallow pills
    • Participant and parent/legal guardian speak, read and understand English
    • Normal ECG and laboratory tests
    • Adequate vision and hearing
    View Trial

    MPST3: Online Problem Solving Skills Training

    Online Implementation of Problem-Solving Skills Training for Parents of Newly Diagnosed Childhood Cancer Patients

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Please see the eligibility section on the clinical trial for full inclusion and exclusion criteria.
    View Trial

    PEESC: Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    PNCQ: Developing a Neurocognitive Questionnaire for Childhood Cancer Survivors

    Assessing Patient-Reported Neurocognitive Functioning in Pediatric Oncology: A Pilot Study Toward Developing the Pediatric Neurocognitive Questionnaire (PNCQ)

    Diseases Treated:

    Cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients and their parents.

    • 8 to 17.9 years old
    • Cancer survivor who is off cancer therapy
    • Parents and legal guardians of children to also enroll in the study
    • Speaks English

     

    View Trial

    SBANK10: Sperm Banking Among Adolescents Newly Diagnosed with Cancer: Development of a Profiling and Referral Tool

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    SEDYC: Social and Emotional Development in Children with Cancer

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients, their parents and patients' teachers.

    • Patient between 4 and 6 years old
    • Primary diagnosis of brain tumor or non-CNS solid tumor
    • 6 to 12 months since therapy was completed (+/- 1 month)
    • Chemotherapy was part of tumor treatment
    • Able to speak and read English
    View Trial

    SJHOME: At-Home Care after Stem Cell Transplant

    Health and Outpatient Management Experiences

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial open only to St. Jude patients.

    • 12 years old or younger
    • Has had a hematopoietic stem cell transplant (HCST)
    • Recruitment occurs within two weeks before or after discharge from transplant admission
    • Prescribed oral medication at discharge
    • Speaks and reads English
    View Trial

    SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors

    Components of Social Functioning in Survivors of Pediatric Brain Tumors

    Diseases Treated:

    Brain tumor

    Eligibility:

    This study is open only to patients at St. Jude Children’s Research Hospital.

    • Diagnosis of medulloblastoma or other brain tumor
    • Between 8 and 12 years old
    • At least 2 years after completion of therapy
    • Full-time student
    • Speaks English
    View Trial

    XPD12-077: Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    St. Jude patients:

    • Treated with an allogeneic bone marrow or stem cell transplant at St. Jude
    • 8 years of age or older
    • Younger than 21 at time of transplant
    • More than 5 years from date of transplant

    Healthy volunteers (comparison group):

    • 8 years of age or older
    • Primarily speaks English
    • No known history of serious illness
    View Trial
  15. PEPR: Patient-Reported Outcomes in Childhood Cancer Survivors

    Validation of Pediatric Patient-Reported Outcomes (PEPR) for Childhood Cancer Survivors

    Diseases Treated:

    Cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients and their parents.

    • St. Jude childhood cancer survivors between 8 and 17 years old
    • Parents of St. Jude childhood cancer survivors
    View Trial

    PNCQ: Developing a Neurocognitive Questionnaire for Childhood Cancer Survivors

    Assessing Patient-Reported Neurocognitive Functioning in Pediatric Oncology: A Pilot Study Toward Developing the Pediatric Neurocognitive Questionnaire (PNCQ)

    Diseases Treated:

    Cancer

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients and their parents.

    • 8 to 17.9 years old
    • Cancer survivor who is off cancer therapy
    • Parents and legal guardians of children to also enroll in the study
    • Speaks English

     

    View Trial

    PRO-CTCAE: Creating and Validating Child Adverse Event Reporting in Oncology Trials: Pediatric PRO-CTCAE Project

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    U-CHAT: Understanding Communication in Health Care to Achieve Trust

    Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    Primary oncologist:

    • Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor Clinic at St. Jude Children’s Research Hospital
    • Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

    Parents of children with cancer:

    • Age 18 or older
    • Biological parent, step-parent or primary legal guardian
    • Reads and speaks English

    Patients:

    • Primary oncologist is enrolled in the study.
    • 30 years old or younger
    • Diagnosed with a solid tumor and/or a brain tumor
    View Trial
  16. DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial

    RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

    A Phase II Trial of Surgery and Fractionated Re-irradiation for Recurrent Ependymoma

    Diseases Treated:

    Recurrent ependymoma

    Eligibility:

    • Progressive intracranial ependymoma after prior focal irradiation
    • At least 1 year old and younger than 21 years old
    • Adequate performance status (ECOG less than 3)
    • Does not require mechanical ventilation
    • Interval from start of initial radiation therapy to enrollment greater than 9 months
    View Trial

    RMS13: Chemotherapy, Surgery and Proton Beam Radiation Therapy in Treating Patients with Newly Diagnosed Rhabdomyosarcoma

    Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Participants with Low-, Intermediate- and High-Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    Diseases Treated:

    Rhabdomyosarcoma (low-risk, intermediate-risk and high-risk)

    Eligibility:

    • Newly diagnosed rhabdomyosarcoma
    • Younger than 22 years (eligible until 22nd birthday)
    • No previous treatment with chemotherapy or radiation therapy
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial
  17. EPSTRV: Retroviral Vector Mediated Globin Gene Transfer to Correct Sickle Cell Anemia or Thalassemia

    Experimental Evaluation of the Potential to Correct the Pathophysiology of Sickle Cell Anemia or Thalassemia by Retroviral Vector Mediated Globin Gene Transfer

    Diseases Treated:

    Sickle cell anemia

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant’s age is equal to or greater than two (2) years old
    • No active sickle cell disease
    • Adequate blood counts
    View Trial

    INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

    Diseases Treated:

    Non-malignant blood diseases (non-therapeutic)

    Eligibility:

    • Receiving therapy or a consultation for a non-malignant blood disorder
    • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
    View Trial

    LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

    Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

    • Diagnosis of sickle cell disease (SCD)
    • 16 to 20 years old
    • English is primary language
    View Trial

    PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease

    Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

    • Between 6 and 25 years old
    • Diagnosed with sickle cell disease
    • Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
    • Speaks English
    View Trial

    REHASH: Barriers to Hydroxyurea Adherence for Sickle Cell Disease

    Re-Aiming at Hydroxyurea Adherence for Sickle Cell with MHealth

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This study is limited to patients living in the Memphis, Tennessee region.

    Phase I

    Phase II

    • Diagnosis of sickle cell disease
    • Between 15 and 44.9 years old
    • Receiving hydroxyurea treatment for sickle cell disease
    • Owns a smart phone
    • Not currently receiving text messages for improving hydroxyurea adherence
    • Not currently undergoing hydroxyurea dose escalation
    • Not on any investigational new drug intervention study for sickle cell disease
    View Trial

    SCCRIP: Sickle Cell Research and Intervention Program

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.
    • Participant has a diagnosis of Sickle Cell Disease of any genotype.
    View Trial

    TADO: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

    A Phase 3 Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    • Participant with Sickle Cell Disease (laboratory determined HbSS or HbS beta zero thalassemia) who have had >2 episodes of Vaso-occlusive crisis in the past year. 
    • Participants >2 years of age and < 18 years of age.
    View Trial
  18. Featured Trial

     
     

    A031102: Standard-Dose Combination Chemotherapy Compared to High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

    A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

    Diseases Treated:

    Germ cell tumors

    Eligibility:

    • 14 years old or older
    • Diagnosis of germ cell tumor (GCT)
    • Previously received 3 to 6 cycles of cisplatin-based chemotherapy
    • No more than one prior line of chemotherapy
    • No prior treatment with high-dose chemotherapy
    View Trial

    ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

    A Phase I/II Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan In Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant is >12 months and < 21 years of age at the time of study entry.
    • Participant has had histologic verification of malignancy at original diagnosis or relapse.
    • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
    • Participant has a relapsed or refractory solid tumor.
    View Trial

    ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

    A Phase I Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

    Diseases Treated:

    Solid Tumors

    Eligibility:

    • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
    • Fully recovered from the acute toxic effects of all prior anticancer therapy
    • At least 1 but not more than 21 years of age
    • Able to swallow tablets whole
    View Trial

    ADV1416: A Study of Ramucirumab in Children with Solid Tumors and Brain Tumors

    A Phase I Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

    Diseases Treated:

    Brain Tumors

    Solid Tumors

    Eligibility:

    • 12 months old or older and younger than 21 years old
    • Diagnosis:
      • Part A - Non-central nervous system (CNS) tumor that returned after treatment or did not respond to treatment
      • Part B – CNS tumor that returned after treatment or did not respond to treatment
    • No other proven therapy options
    View Trial

    ADVL1513: Entinostat for Children with Recurrent or Refractory Solid Tumors

    A Phase I Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

    Diseases Treated:

    Solid Tumor, CNS Tumor, Lymphoma

    Eligibility:

    • 12 months to 21 years old
    • Able to swallow whole tablets
    • Diagnosis of recurrent or refractory solid tumor, including CNS tumor and lymphoma
    View Trial

    ADVL1515: Prexasertib for Children with Recurrent or Refractory Solid Tumors

    A Phase I Study of LY2606368 (prexasertib mesylate monohydrate), A CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

    Diseases Treated:

    Solid Tumor, CNS Tumor

    Eligibility:

    • 12 months to 21 years old
    • Diagnosis of recurrent or refractory solid tumor, including CNS tumor
    View Trial

    ANBLB1: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Neuroblastoma Biology Studies

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • All newly diagnosed suspected:
      • neuroblastoma,
      • ganglioneuroblastoma, or 
      • ganglioneuroma (maturing subtype) patients
    • Less than or equal to 21 years of age
    • Seen at Children's Oncology Group (COG) institutions
    View Trial

    AOST1421: Combination Drug Therapy to Treat Patients with Recurrent Osteosarcoma

    A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma

    Diseases Treated:

    Osteosarcoma

    Eligibility:

    • Younger than 30 years old
    • Original diagnosis of osteosarcoma
    • Osteosarcoma has come back in the lungs after original treatment
    • Lung tumors have been removed surgically within the last 4 weeks before enrolling in the study
    View Trial

    BMNIRN: Talazoparib Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

    A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant has refractory or recurrent solid tumor for which there is no standard therapy.
    • Participant has had histologic verification of malignancy at original diagnosis or at the time of relapse.
    • Participant is twelve (12) months to twenty-five (25) years of age at the time of enrollment on study.
    • Participant life expectancy is at least eight (8) weeks. 
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advance BRAF V600-Mutation Positive Solid Tumors

    Diseases Treated:

    Solid tumors, giomas, hystiocytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial

    EWS1221: Phase III Study of Ganitumab with Chemotherapy for Patients with Metastatic Ewing Sarcoma

    Randomized Phase III Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

    Diseases Treated:

    Ewing sarcoma

    Eligibility:

    • Younger than or equal to 50 years old
    • Diagnosis of Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow or other metastatic site
    View Trial

    FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

    18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

    Diseases Treated:

    Neuroblastoma, pheochromocytoma

    Eligibility:

    This study is open to St. Jude patients only.

    • Known or suspected neuroblastoma or pheochromocytoma
    • At least 1 year old

     

    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    IPACTR: International Pediatric Adrenocortical Tumor Registry

    Diseases Treated:

    Adrenocortical tumors (carcinoma and adenoma)

    Eligibility:

    • Diagnosis of an adrenocortical tumor (ACT)
    • 21 years of age or younger at diagnosis
    • Relatives of patients with ACT
    View Trial

    iRET: Intravitreal Chemotherapy for Children with Retinoblastoma

    Intravitreal Carboplatin for the Treatment of Participants with Recurrent or Refractory Intraocular Reintoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Age 17 or younger
    • Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
    View Trial

    LILOLA: A Study of Olaratumab Alone and in Combination with Standard Chemotherapies in Children with Cancer

    A Study of Olaratumab Alone and in Combination with Standard Chemotherapies in Children with Cancer

    Diseases Treated:

    Cancer

    Eligibility:

    • Younger than 18 years old
    • Diagnosis of solid tumor that has not responded to treatment or came back after treatment (excluding melanoma and lymphomas)

     

    View Trial

    LITE: Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed with Solid Tumors: A Pilot Study

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • At least 12 years old 
    • Diagnosed with a solid tumor or lymphoma within the past 30 days 
    • Speaks, reads and writes in English or Spanish
    • No blindness or history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems 
    • Not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months
    • No laser corrective eye surgery in the past 30 days
    View Trial

    LOXO-TRK: Testing Larotrectinib (LOXO-101) in Children with Advanced Solid Tumors or Brain Tumors

    A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors (LOXO-TRK-15003)

    Diseases Treated:

    Solid Tumors, Central Nervous System Tumors

    Eligibility:

    Phase 1

    • Birth through 21 years of age with locally advanced or metastatic solid tumor or primary CNS tumor that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Infants from birth and older with diagnosis of malignancy and with documented NTRK fusion that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
    • Patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery or limb amputation to achieve complete surgical resection

    Phase 2

    • Infants from birth and older at C1D1 with locally advanced or metastatic infantile fibrosarcoma OR
    • Birth through 21 years old at C1D1 with locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was not responsive to therapy and for which no standard or available curative therapy with a NTRK gene funsion OR
    • More than 21 years old with tumor diagnosis typical of a pediatric patient and an NTRK fusion
    View Trial

    MACMEL: A Study to Analyze Melanoma Lesions in Children and Teens

    Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

    Diseases Treated:

    Melanoma

    Eligibility:

    • Diagnosed with a melanoma tumor that is malignant (cancerous) or that might be cancerous, including:
      • Conventional or “adult-type” melanoma
      • Spitzoid melanoma/atypical Spitz tumor
      • Congenital melanoma
      • Melanoma arising in a giant congenital nevus
      • Melanocytic lesions with indeterminate biological behavior (e.g., pigment-synthesizing melanomas)
    • Younger than 19 years of age 
    View Trial

    MARB: Molecular Analysis of Retinoblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

    Diseases Treated:

    Relapsed or refractory solid tumor

    Eligibility:

    • Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma

    Eligibility:

    • Between 6 months and 18 years old with  diagnosis of advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma, or MSI-H solid tumor
      OR
    • Between 3 and 18 years of age with relapsed or refractory classical Hodgkin lymphoma
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

    Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    • Younger than 19 years old
    • Newly diagnosed, advanced stage, high-risk neuroblastoma
    • Histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine
    • Adequate kidney and liver functions
    View Trial

    NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (ANBL1232)

    Diseases Treated:

    Neuroblastoma, ganglioneuroblastoma

    Eligibility:

    • Participant has been enrolled on ANBLB1 (ANBL00B1).
    • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
    • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

     

    View Trial

    PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

    A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; anti PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG), DIPGs and Hypermutated Brain Tumors

    Diseases Treated:

    Recurrent, progressive, or refractory high-grade gliomas

    Eligibility:

    • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
    • Participant is 1 to 18 years of age
    • Participant has bi-measurable disease on MRI 
    • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

     

    View Trial

    RBAPP: Smartphone App for Retinoblastoma

    Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • 7 years old or younger
    • Part I
      • Diagnosed with retinoblastoma and has not received any treatment OR
      • Diagnosed with cataracts and has not received any treatment OR
      • Diagnosed with glaucoma and has not received any treatment
    • Part II
      • Referred to an eye doctor to check for leukocoria or other eye conditions
    • Part III
      • Diagnosed with retinoblastoma and is receiving treatment
    View Trial

    RETCELL: A Study of Children with Heritable Retinoblastoma

    Feasibility, Validation and Differentiation of Induced Pluripotent Stem Cells Produced from Patients with Heritable Retinoblastoma

    Diseases Treated:

    Retinoblastoma (non-therapeutic)

    Eligibility:

    Family history of retinoblastoma with one of the following:

    • RB1 mutation OR
    • Diagnosis of bilateral retinoblastoma OR
    • Diagnosis of unilateral retinoblastoma with RB1 mutation or MYCN amplification
    View Trial

    RMS13: Chemotherapy, Surgery and Proton Beam Radiation Therapy in Treating Patients with Newly Diagnosed Rhabdomyosarcoma

    Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Participants with Low-, Intermediate- and High-Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    Diseases Treated:

    Rhabdomyosarcoma (low-risk, intermediate-risk and high-risk)

    Eligibility:

    • Newly diagnosed rhabdomyosarcoma
    • Younger than 22 years (eligible until 22nd birthday)
    • No previous treatment with chemotherapy or radiation therapy
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial

    SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

    Phase II Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

    Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Newly diagnosed retinoblastoma that has not spread beyond the eye
    • Has not received previous treatment with chemotherapy or radiation therapy
    • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
    View Trial

    U-CHAT: Understanding Communication in Health Care to Achieve Trust

    Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    Primary oncologist:

    • Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor Clinic at St. Jude Children’s Research Hospital
    • Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

    Parents of children with cancer:

    • Age 18 or older
    • Biological parent, step-parent or primary legal guardian
    • Reads and speaks English

    Patients:

    • Primary oncologist is enrolled in the study.
    • 30 years old or younger
    • Diagnosed with a solid tumor and/or a brain tumor
    View Trial
  19. ANBLB1: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Neuroblastoma Biology Studies

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • All newly diagnosed suspected:
      • neuroblastoma,
      • ganglioneuroblastoma, or 
      • ganglioneuroma (maturing subtype) patients
    • Less than or equal to 21 years of age
    • Seen at Children's Oncology Group (COG) institutions
    View Trial

    IPACTR: International Pediatric Adrenocortical Tumor Registry

    Diseases Treated:

    Adrenocortical tumors (carcinoma and adenoma)

    Eligibility:

    • Diagnosis of an adrenocortical tumor (ACT)
    • 21 years of age or younger at diagnosis
    • Relatives of patients with ACT
    View Trial

    MARB: Molecular Analysis of Retinoblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    SBANK10: Sperm Banking Among Adolescents Newly Diagnosed with Cancer: Development of a Profiling and Referral Tool

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    TBANK: Protocol for Collecting, Banking, and Distributing Human Tissue Samples: St. Jude Children’s Research Hospital Biorepository

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial
  20. FLUTRAN: Flu Vaccine Dose Comparison in Children Who Have Had Stem Cell Transplants

    Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients

    Diseases Treated:

    Influenza

    Eligibility:

    • At least 3 years old and younger than 17
    • Allogeneic hematopoietic stem cell transplant recipient
    • At least 3 and not more than 35 months after transplant
    • Platelet count of at least 30,000
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial